Welcoming Tyler Piazza, Partnerships Director, HEOR and hēRo3, within our policy, access, value, and evidence capability

We are pleased to welcome Tyler Piazza to his new role, Partnerships Director, HEOR and hēRo3, within our policy, access, value, and evidence capability. In this update, Tyler shares his thoughts on bettering the HEOR modeling capabilities for early pipeline assets, and explains how he will be creating the connections that make better health happen.

Improving patient lives through better access to innovative therapies 

I’m thrilled to join the policy, access, value, and evidence capability at Fishawack Health, bringing with me 10+ years of academic and industry experience in the life sciences and a deep focus in real-world evidence (RWE) and health economics and outcomes research (HEOR). 

After building this expertise at a life science strategy consultancy, I transitioned to a population genomics business, where I helped connect biopharma partners with clinical development and real-world data solutions. 

In addition to earning my graduate degree in molecular biology, I have studied cancer drug discovery and molecular genetics in several world-class research labs. The problem-solving skills that I developed in the lab led to a natural progression into life science strategy consulting. 

It was here that I specialized in RWE and HEOR, and discovered a passion for bringing creative, data-forward and high-impact solutions to the industry. Our hēRo3 platform is exactly this, and I couldn’t be more excited to introduce this much-needed solution to the industry. 

My career journey has had many highlights, including: 

• supporting more than two dozen biopharma companies in better understanding and implementing their pipeline commercialization activities across 70+ unique RWE and HEOR consulting engagements 
  
  
• leading the launch and development of multiple ongoing community and industry-specific ventures, including a leading Boston-based professional networking organization 
  
  
• multiple patents and publications in notable scientific journals, including Nature Communications and Nature Cell Biology. 
  
  

Bettering the modeling capabilities of HEOR professionals 

I am looking forward to meeting with external client partners to understand their biggest pain points and provide meaningful value-based solutions. 

HEOR, RWE, and market access teams are becoming more and more critical to the success of new therapies. Despite the ever-increasing demand for evidence-based value from regulatory bodies, payers, and the like, there has been little advancement in terms of the tools available for generating and analyzing these insights. 

Traditional HEOR modeling requires labor-intensive methods that can take months to get an answer that hēRo3 can produce in minutes. Accelerating the return of these results allows early-pipeline development teams to make crucial decisions faster and more effectively. 

This new role will help equip our life science partners with hēRo3 to dramatically improve their HEOR modeling capabilities and speed to market. I would love to see industry-wide adoption of hēRo3 – this platform is such a game changer that it will become as ubiquitous for early-pipeline HEOR modeling as PowerPoint is for creating presentations. 

Please get in touch with me to discuss your HEOR challenges and business needs. 
 

Integrity and trust are the foundations of creating the connections that make better health happen 

One of the things I look forward to most in this role is the opportunity to connect and build relationships with amazing leaders who want to make a real difference in the industry. 

It brings me joy when I can create legitimate value for a partner, but this can’t be achieved without first establishing trust in the relationship. 

Similarly, I feel that our company value of integrity is critical in this industry. Patients are at the beginning, middle, and end of everything we do – they are the ones who stand to benefit from the work we put out there. In HEOR, we oversee the quantification of the value a therapy will have for patients. It’s therefore imperative that we act with uncompromising integrity to ensure the safe and effective creation of new medicines and devices. 

We are always looking for people who will deliver first-class work 

If you’d like to find out more about career opportunities within our organization, please look through our current vacancies or get in touch with your CV.